{
    "clinical_study": {
        "@rank": "122728", 
        "brief_summary": {
            "textblock": "Background:\n\n        -  Malignant mesothelioma is a malignancy arising from the mesothelial cells of the\n           pleura, peritoneum, pericardium, or tunica vaginalis.\n\n        -  Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant\n           pleural mesothelioma is the most common of these, comprising of 80% of the cases with\n           an annual incidence of about 2,500 in the United States.\n\n        -  The median survival from diagnosis of pleural mesothelioma is approximately 12 months.\n           The majority of patients present with stage III or IV disease with 85-90% of patients\n           considered unresectable at diagnosis.\n\n        -  Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless,\n           patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment\n           options due in large part to the rarity of the disease.\n\n      Objectives:\n\n      -To allow sample acquisition for use in the study of mesothelioma.\n\n      Eligibility:\n\n        -  All patients age greater than or equal to 2 years with malignant mesothelioma\n\n        -  Must be able and willing to provide informed consent if 18 or over; parent or guardian\n           must be able and willing to provide consent for patients under the age of 18\n\n      Design:\n\n        -  Up to 1000 subjects will be enrolled.\n\n        -  Patients will be followed to determine the course of disease and to record any\n           treatment received for mesothelioma.\n\n        -  Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for\n           tissue banking.\n\n        -  Studies which may be performed on banked material include genetic and genomic studies,\n           establishment of cell cultures and immunologic studies."
        }, 
        "brief_title": "Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma", 
        "completion_date": {
            "#text": "July 2033", 
            "@type": "Anticipated"
        }, 
        "condition": "Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "detailed_description": {
            "textblock": "Background:\n\n        -  Malignant mesothelioma is a malignancy arising from the mesothelial cells of the\n           pleura, peritoneum, pericardium, or tunica vaginalis.\n\n        -  Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant\n           pleural mesothelioma is the most common of these, comprising of 80% of the cases with\n           an annual incidence of about 2,500 in the United States.\n\n        -  The median survival from diagnosis of pleural mesothelioma is approximately 12 months.\n           The majority of patients present with stage III or IV disease with 85-90% of patients\n           considered unresectable at diagnosis.\n\n        -  Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless,\n           patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment\n           options due in large part to the rarity of the disease.\n\n      Objectives:\n\n      -To allow sample acquisition for use in the study of mesothelioma.\n\n      Eligibility:\n\n        -  All patients age greater than or equal to 2 years with malignant mesothelioma\n\n        -  Must be able and willing to provide informed consent if 18 or over; parent or guardian\n           must be able and willing to provide consent for patients under the age of 18\n\n      Design:\n\n        -  Up to 1000 subjects will be enrolled.\n\n        -  Patients will be followed to determine the course of disease and to record any\n           treatment received for mesothelioma.\n\n        -  Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for\n           tissue banking.\n\n        -  Studies which may be performed on banked material include genetic and genomic studies,\n           establishment of cell cultures and immunologic studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  INCLUSION CRITERIA:\n\n          -  All patients with malignant mesothelioma.\n\n          -  Confirmed pathological diagnosis is required from the Laboratory of Pathology, NCI.\n             Tumor tissue that has been previously collected and is available for study or that\n             can be collected with minimal additional risk to the subject during sampling required\n             for routine patient care or required testing on an NIH research protocol will be used\n             for diagnosis.\n\n          -  Age greater than or equal to2years\n\n          -  Ability and willingness of subject or legally authorized representative (LAR) to\n             provide informed consent to participation.\n\n        EXCLUSION CRITERIA:\n\n          -  Active symptomatic major organ disorder that would increase the risk of biopsy,\n             including but not limited to ischemic heart disease, recent myocardial infarction,\n             active congestive heart failure, pulmonary dysfunction.\n\n          -  Pregnant or breast feeding women will be eligible for this protocol, but will not\n             undergo tumor biopsy.\n\n          -  Active concomitant medical or psychological illnesses that may increase the risk to\n             the subject or in adult patients, inability to obtain informed consent, at the\n             discretion of the principal investigator.\n\n          -  Recruitment strategies:\n\n               -  All patients who are screened for treatment protocols or who seek second\n                  opinions in the mesothelioma clinic of the NCI will be screened for this\n                  protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950572", 
            "org_study_id": "130202", 
            "secondary_id": "13-C-0202"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Samples", 
            "Biobank", 
            "Pleural Mesothelioma", 
            "Peritoneal Mesothelioma"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "NIH Clinical Center Detailed Web Page", 
            "url": "http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2013-C-0202.html"
        }, 
        "location": {
            "contact": {
                "last_name": "For more information at the NIH Clinical Center contact National Cancer Institute Referral Office", 
                "phone": "888-624-1937"
            }, 
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institutes of Health Clinical Center, 9000 Rockville Pike"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma", 
        "overall_contact": {
            "email": "bengtsonla@mail.nih.gov", 
            "last_name": "Lisa A Bengtson, R.N.", 
            "phone": "(301) 435-5398"
        }, 
        "overall_contact_backup": {
            "email": "rh276q@nih.gov", 
            "last_name": "Raffit Hassan, M.D.", 
            "phone": "(301) 451-8742"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Raffit Hassan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2033", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "allow sample acquisition for use in the study of mesothelioma", 
            "safety_issue": "No", 
            "time_frame": "ongoin"
        }, 
        "reference": [
            {
                "PMID": "17534390", 
                "citation": "Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007 Jun;4(6):344-52. Review."
            }, 
            {
                "PMID": "19650718", 
                "citation": "Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39(7):576-88. Review."
            }, 
            {
                "PMID": "17955087", 
                "citation": "Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007 May 10;9(2):32. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950572"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}